Wall Street Zen Downgrades Evotec (NASDAQ:EVO) to Sell

Evotec (NASDAQ:EVO) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities analysts have also weighed in on EVO. HC Wainwright started coverage on shares of Evotec in a report on Wednesday, April 15th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings raised Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Finally, Berenberg Bank initiated coverage on Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.00.

Evotec Price Performance

Evotec stock opened at $3.07 on Friday. Evotec has a 52-week low of $2.31 and a 52-week high of $4.80. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68. The stock’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $3.21.

Evotec (NASDAQ:EVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share for the quarter. Evotec had a negative net margin of 26.20% and a negative return on equity of 24.93%. The company had revenue of $297.02 million during the quarter. As a group, equities analysts forecast that Evotec will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its holdings in Evotec by 25.7% during the fourth quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after buying an additional 367,545 shares in the last quarter. DCF Advisers LLC lifted its stake in Evotec by 7.6% during the 3rd quarter. DCF Advisers LLC now owns 1,198,993 shares of the company’s stock valued at $4,352,000 after acquiring an additional 84,500 shares in the last quarter. WCM Investment Management LLC lifted its stake in Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock valued at $1,480,000 after acquiring an additional 67,917 shares in the last quarter. ABC Arbitrage SA boosted its holdings in Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after acquiring an additional 422,230 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Evotec in the 4th quarter worth $565,000. Institutional investors own 5.81% of the company’s stock.

Evotec News Summary

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Evotec AG (NASDAQ:EVO) and kept a $7.00 price target, citing a path to improving earnings over the next few years.
• Positive Sentiment: The firm lifted its Q4 2026 EPS estimate to $0.01 from a prior loss expectation, suggesting improving near-term profitability.
• Neutral Sentiment: The analyst maintained relatively constructive forecasts for FY2027-FY2029, but still expects only modest earnings, with some of those estimates slightly reduced. Article Title
• Negative Sentiment: Recent earnings coverage indicated Evotec reported a wider quarterly loss and missed revenue expectations, which could weigh on the stock.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.